Sugi Predict

Sugi Predict / Compounds / SCHEMBL6900306

SCHEMBL6900306

SCHEMBL6900306

COc1ccc(Cn2cnc3nc(Cl)nc(Cl)c32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 1/20 0.47
▸ GAA P10253 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CYP11B2 P19099 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP11B1 P15538 2/20 0.41
▸ CCNE2 O96020 1/20 0.41
▸ CCNE1 P24864 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ YTHDC1 Q96MU7 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ CMA1 P23946 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30020920 1.00 MET (0.47) METGAAMAPTMEN1KMT2A
SCHEMBL21883518 0.88 MET (0.46) METGAAMAPTMEN1KMT2A
SCHEMBL30021455 0.88 MET (0.46) METGAAMAPTMEN1KMT2A
SCHEMBL12808668 0.87 NPSR1 (0.49) METGAAMAPTMEN1KMT2A
SCHEMBL5462813 0.87 MET (0.51) METGAAMAPTMEN1KMT2A
SCHEMBL23322463 0.84 HPGD (0.35) METGAAMEN1KMT2AL3MBTL1
SCHEMBL5460434 0.84 MET (0.48) METGAAMAPTMEN1KMT2A
SCHEMBL30496439 0.84 HPGD (0.35) METGAAMEN1KMT2AL3MBTL1
SCHEMBL29434725 0.82 ALDH1A1 (0.52) METGAAMAPTMEN1KMT2A
SCHEMBL20187539 0.82 ALDH1A1 (0.52) METGAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333424-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2025-10-30 — — US disclosed
CN-115244054-B Crystals of hypoxanthine compound 橘生药品工业株式会社 2024-07-16 — — CN disclosed
CN-112673008-B Hypoxanthine compounds 橘生药品工业株式会社 2023-07-18 — — CN disclosed
US-20230183241-A1 CRYSTAL OF A HYPOXANTHINE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2023-06-15 — — US disclosed
EP-4092028-A1 CRYSTAL OF HYPOXANTHINE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2022-11-23 — — EP disclosed
CN-115244054-A Crystals of hypoxanthine compound 橘生药品工业株式会社 2022-10-25 — — CN disclosed
US-20210214357-A1 HYPOXANTHINE COMPOUNDS KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-07-15 — — US disclosed
US-20210214357-A1 HYPOXANTHINE COMPOUNDS KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-07-15 — — US disclosed
EP-3819299-A1 HYPOXANTHINE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-05-12 — — EP disclosed
EP-3819299-A1 HYPOXANTHINE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2021-05-12 — — EP disclosed
US-8372852-B2 Purines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2013-02-12 — — US disclosed
WO-2013006526-A2 TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-10 — — WO disclosed
US-20120277206-A1 REVERSE TRANSCRIPTASE INHIBITORS Andrea Boesciences, Inc. (US) 2012-11-01 — — US disclosed
US-8207178-B2 Fused pyrimidines as reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2012-06-26 — — US disclosed
US-8026245-B2 HIV replication inhibiting purine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2011-09-27 — — US disclosed
US-8026245-B2 HIV replication inhibiting purine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2011-09-27 — — US disclosed
WO-2011058025-A1 N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-05-19 — — WO disclosed
US-20110086840-A1 N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2011-04-14 — — US disclosed
WO-2009079412-A2 REVERSE TRANSCRIPTASE INHIBITORS ARDEA BIOSCIENCES INC. (US) 2009-06-25 — — WO disclosed
US-20090162319-A1 REVERSE TRANSCRIPTASE INHIBITORS ARDEA BIOSCIENCES (US) 2009-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333424-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, IRF3 MET 3880/4885GAA 115/4885MAPT 2776/4885
US-20120277206-A1 REVERSE TRANSCRIPTASE INHIBITORS POLRMT, POLR1E, TYMP MET 4623/4885GAA 120/4885MAPT 1376/4885
US-20090162319-A1 REVERSE TRANSCRIPTASE INHIBITORS POLRMT, POLR1E, TYMP MET 4623/4885GAA 120/4885MAPT 1376/4885
US-20230183241-A1 CRYSTAL OF A HYPOXANTHINE COMPOUND HPRT1, TPMT, NUDT1 MET 2338/4885GAA 354/4885MAPT 815/4885
US-20110086840-A1 N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE P2RX7, P2RY1, PNP MET 4621/4885GAA 3006/4885MAPT 4237/4885
US-20210214357-A1 HYPOXANTHINE COMPOUNDS HPRT1, DHPS, PAH MET 3359/4885GAA 952/4885MAPT 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.